Clinical trials for Von Hippel-Lindau disease
16 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGPhase 3NCT07405164Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)Merck Sharp & Dohme LLC · PI: Medical Director
- RECRUITINGPhase 2NCT07171905CAT-VHL Exploring the Role of Carbonic Anhydrase IX as Diagnostic and Theranostic Target in Von-Hippel Lindau DiseaseIRCCS Ospedale San Raffaele
- ENROLLING BY INVITATIONN/ANCT05737602Promoting Stress Management and Resilience Among Individuals With Von Hippel- Lindau DiseaseMassachusetts General Hospital · PI: Giselle Perez, PhD
- RECRUITINGPhase 2NCT07167329Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL TrialJosé Claudio Casali da Rocha · PI: José Claudio Casali da Rocha, Head of Oncogenetics
- RECRUITINGNCT05955014Data Collection Protocol for Patients With Von Hippel Lindau DiseaseM.D. Anderson Cancer Center · PI: Eric Jonasch, MD
- RECRUITINGNCT06194669Mechanisms of Somatic Mutation and Tumor Initiation in Pre-malignant Kidney Tubule CellsIRCCS San Raffaele · PI: Irene Franco, PhD
- RECRUITINGN/ANCT05424016Propranolol and Von Hippel-Lindau DiseaseAssistance Publique - Hôpitaux de Paris
- RECRUITINGPhase 2NCT04924075Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)Merck Sharp & Dohme LLC · PI: Medical Director
- ACTIVE NOT RECRUITINGNCT04458935Retrospective Case Series of Trans-scleral Cryotherapy for Retinal HemangioblastomaNational Eye Institute (NEI) · PI: Emily Y Chew, M.D.
- RECRUITINGPhase 2NCT04074135Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine TumorsNational Cancer Institute (NCI) · PI: Naris Nilubol, M.D.
- ACTIVE NOT RECRUITINGPhase 2NCT03401788A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · PI: Medical Director
- RECRUITINGNCT01496625National Eye Institute Biorepository for Retinal DiseasesNational Eye Institute (NEI) · PI: Tiarnan DL Keenan, M.D.
- RECRUITINGNCT03749980MyVHL: Patient Natural History StudyJoshua Mann, MPH · PI: Joshua Mann, MPH
- RECRUITINGNCT02420067Screening for Endolymphatic Sac Tumours (ELSTs) in Von Hippel-Lindau (vHL) PatientsMarie Luise Bisgaard, MD · PI: Marie Luise Bisgaard, M.D.
- ENROLLING BY INVITATIONN/ANCT00102544Use of Tracking Devices to Locate Abnormalities During Invasive ProceduresNational Institutes of Health Clinical Center (CC) · PI: Peter A Pinto, M.D.
- ACTIVE NOT RECRUITINGNCT00005902Study of Brain and Spinal Cord Tumor Growth and Cyst Development in Patients With Von Hippel Lindau DiseaseNational Institute of Neurological Disorders and Stroke (NINDS) · PI: Prashant Chittiboina, M.D.